Oppenheimer Holdings Inc. set a $10.00 price objective on Trevena Inc (NASDAQ:TRVN) in a research note published on Thursday, May 4th. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
A number of other research firms also recently commented on TRVN. Roth Capital set a $9.00 price objective on Trevena and gave the stock a buy rating in a research note on Wednesday, February 22nd. HC Wainwright dropped their price objective on Trevena from $11.00 to $8.00 and set a buy rating on the stock in a research note on Thursday, February 23rd. Cowen and Company reissued a buy rating on shares of Trevena in a research note on Tuesday, February 21st. Jefferies Group LLC reissued a buy rating and issued a $11.00 price objective on shares of Trevena in a research note on Thursday, February 16th. Finally, Ladenburg Thalmann Financial Services began coverage on Trevena in a research note on Thursday, February 2nd. They issued a buy rating and a $15.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of $11.73.
Trevena (NASDAQ:TRVN) traded down 0.32% during midday trading on Thursday, reaching $3.09. 378,285 shares of the company were exchanged. The company has a 50 day moving average of $3.30 and a 200-day moving average of $4.96. Trevena has a 52-week low of $3.07 and a 52-week high of $8.03. The company’s market capitalization is $180.15 million.
Trevena (NASDAQ:TRVN) last announced its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.19. Trevena had a negative return on equity of 66.50% and a negative net margin of 841.00%. On average, equities research analysts anticipate that Trevena will post ($1.51) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This article was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.chaffeybreeze.com/2017/05/20/trevena-inc-trvn-given-a-10-00-price-target-at-oppenheimer-holdings-inc-updated.html.
A number of institutional investors have recently bought and sold shares of TRVN. Northpointe Capital LLC boosted its position in Trevena by 170.0% in the first quarter. Northpointe Capital LLC now owns 1,163,184 shares of the biopharmaceutical company’s stock valued at $4,269,000 after buying an additional 732,365 shares during the period. Baker BROS. Advisors LP purchased a new position in Trevena during the third quarter valued at approximately $3,038,000. Paulson & CO. Inc. purchased a new position in Trevena during the first quarter valued at approximately $1,496,000. Palo Alto Investors LLC purchased a new position in Trevena during the first quarter valued at approximately $1,253,000. Finally, FMR LLC boosted its position in Trevena by 4.5% in the first quarter. FMR LLC now owns 7,037,804 shares of the biopharmaceutical company’s stock valued at $25,828,000 after buying an additional 304,256 shares during the period. 69.28% of the stock is owned by hedge funds and other institutional investors.
Trevena Company Profile
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
Receive News & Ratings for Trevena Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc and related companies with MarketBeat.com's FREE daily email newsletter.